Poly(ADP-ribose)polymerase (PARP)14-a member of the B aggressive lymphoma (BAL) family of macrodomain-containing PARPs-is an ADP ribosyltransferase that interacts with Stat6, enhances induction of certain genes by IL-4, and is expressed in B lymphocytes. We now show that IL-4 enhancement of glycolysis in B cells requires PARP14 and that this process is central to a role of PARP14 in IL-4-induced survival. Thus, enhancements of AMP-activated protein kinase activity restored both IL-4-induced glycolytic activity in Parp14 −/− B cells and prosurvival signaling by this cytokine.
M
echanisms promoting cell survival are central to both physiological homeostasis and cancer. The immune system in particular depends on a reservoir of naïve lymphocytes in the G 0 stage of the cell cycle. Maintenance of this pool requires regulation of energy balance to promote cell survival while preserving a readiness to mobilize in response to a pathogen (1) (2) (3) . Such maintenance depends on cytokines to trigger signal transduction pathways that prevent atrophy and subsequent apoptosis (4) . Members of the cytokine group binding to hematopoietin receptors in the common γ-chain (γ c ) family, such as IL-4 and IL-7, play a crucial role in lymphocyte survival through signals downstream from Janus-family (Jak) kinases (5) (6) (7) . Multiple classes of cytokines and growth factors initiate prosurvival signaling to regulate apoptosis in oncogenesis as well as immunity (1, 2) . Tumors also are notable for cellular metabolic programs differing from their normal cellular counterparts (8, 9) . These parallels between lymphocyte homeostasis and cancer cell physiology are underscored by findings indicating that the γ c cytokine IL-7 promotes lymphocyte survival in G 0 and energetics that favor this outcome, but when overexpressed can drive lymphoma formation in mice (1, 7, 10) .
Among cytokines in the γ c family, interleukin-4 (IL-4) regulates vital cellular processes including lymphocyte differentiation, proliferation, and apoptosis (6) . Moreover, IL-4 may parallel IL-7 in its ability to promote tumorigenesis (11) , but IL-4 activates signaling components distinct from those induced by other cytokines in the γ c family. Thus, IL-4-induced activity of the same Jak kinases as IL-7 causes phosphorylation of a conserved tyrosine residue in an N-P-X-Y motif unique to the IL-4 receptor (6) . This site recruits insulin receptor substrate-2 (IRS-2), which associates with the p85α regulatory subunit of phosphatidylinositol 3-kinase (PI3K) and leads to enhanced Akt kinase activity as well as apoptosis inhibition (6) . Thus, IL-4 is thought to promote lymphocyte survival through an IRS-2-dependent PI3K-Akt pathway analogous to one used by growth factor receptors.
IL-4 also is unique among γ c cytokines in that it mobilizes Jakmediated tyrosine phosphorylation of latent cytoplasmic Stat6 (signal transducer and activators of transcription 6) proteins in resting lymphocytes rather than Stat5 (5, 12) . Tyrosine-phosphorylated Stat6 proteins dimerize, translocate to the nucleus, and bind to specific DNA sequences to regulate gene transcription (12) . However, specific transcriptional cofactors and mechanisms used by Stat6 to mediate target gene regulation or specificity under physiological conditions are poorly understood. Furthermore, the extent to which Stat6 is vital for survival, and the mechanisms by which a Stat6 limb of IL-4-activated signaling pathways might function, remains to be elucidated.
Previous work identified a novel Stat6-interacting protein that influenced IL-4-induced gene expression (13) . This partner of Stat6 encodes an ADP ribosyltransferase whose activity can participate in amplifying Stat6-mediated promoter induction (13) (14) (15) . Mice lacking this protein, renamed PARP14 (13) , contained normal numbers of B and T lymphocytes, but the proliferative response of anti-IgM-stimulated PARP14-null B cells to IL-4 was decreased, as was the induction of two genes that encode prosurvival proteins (15) . These findings suggest that PARP14 is a coactivator of Stat6 at some target genes. Other work in a sarcoma cell line determined that human PARP14 regulates the ubiquitination and levels of phosphoglucose isomerase, a protein involved in intermediary metabolism (16) . These latter results suggested a potential link between PARP14 and cellular metabolism. PARP14 and its impact on modifiers of B-lymphoid oncogenesis were particularly notable because PARP14 is overexpressed in mouse B-lymphoma cells and closely related to the human protein BAL/PARP9, heightened expression of which correlated with worse clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) (17) .
We show here that IL-4 regulation of glycolysis and glucose oxidation requires PARP14. The metabolic state of the cells appears vitally linked to the prosurvival effects of IL-4. PARP14 is needed to achieve full prosurvival signaling by IL-4 in B cells. Inhibition of AMP-activated protein kinase (AMPK), a sensor of cellular energy status and metabolism (18) , blocked IL-4-induced B-cell survival and glycolysis. Conversely, AMPK-activating interventions coordinately restored the glycolytic and prosurvival signaling of IL-4 in Parp14-null B cells. Strikingly, this macro-PARP facilitated B-lymphoid oncogenesis and alterations in developmental progression driven by c-Myc. Together, the data indicate that PARP14 accelerates lymphoma and regulates cellular energy metabolism to promote B-cell survival.
Results

PARP14
Mediates IL-4-Induced Protection Against Apoptosis. Cytokines such as IL-4 inhibit the atrophy and subsequent apoptosis of lymphocytes removed from their normal microenvironment. There is evidence indicating that IL-4-induced Stat6 contributes to B-cell survival (19, 20) . Starting after 9 h in short-term culture, wild-type (WT) B cells removed from their normal environment underwent substantial apoptosis that was decreased by IL-4 ( Fig.  1A and Fig. S1 A-C) . This rescue was attenuated in both Parp14 −/− and Stat6 −/− B cells ( Fig. 1 A and B and Fig. S1 D and E). In addition to Stat6 induction, IL-4 receptors signal through PI3K and the activating phosphorylation of Akt (5, 6) . As expected, IL-4 treatment of WT B cells induced Akt phosphorylation at the T308 and S473 regulatory sites (Fig. 1C and Fig. S2 ). Parp14
and Stat6 −/− B cells each showed normal Akt phosphorylation in response to IL-4. Akt acts in part by phosphorylating GSK3β and the transcription factors Foxo1 and 3a (21) . Although PARP14 has been reported to influence protein stability (16) , absolute levels and IL-4-induced phosphorylation of these downstream targets of Akt were intact in PARP14-and Stat6-null B cells (Fig.  1D) . Thus, PARP14 mediates IL-4-induced rescue of B cells from apoptosis without apparent impact on Akt.
PARP14 Is Essential for IL-4 Regulation of Glycolysis in B Cells. Glucose metabolism plays a critical role in cell survival (22, 23) , so glycolytic rates were assayed in B cells from WT, Parp14 −/− , and Stat6 −/− mice after culture in the presence or absence of IL-4. IL-4 increased rates of glycolysis in WT B cells, but this effect was impaired in B cells lacking either PARP14 or Stat6 ( Fig. 2A) .
The impairment of IL-4-induced glycolysis in Parp14
−/− B cells was not due to a global loss of their capacity to increase metabolism, as anti-IgM stimulation enhanced glycolysis in PARP14-and Stat6-null B cells to levels comparable to WT B cells (Fig. 2B ). IL-4, which collaborates with B-cell receptor cross-linking to enhance proliferation (5, 6, 15, 24) , increased the glycolytic response to anti-IgM in WT, but not PARP14-or Stat6-null, B cells (Fig. 2B) . Indeed, the quantitative increase in glycolysis stimulated by IL-4 was greater in anti-IgM-stimulated B cells than in their resting counterparts (Fig. 2C ). Glycolytic flux in T cells may be limited by transport of glucose, which can be increased by the γ c cytokine IL-7 (7). IL-4 treatment increased glucose uptake into B cells by a PARP14-and Stat6-dependent mechanism, whereas rates of lipopolysaccharide (LPS)-stimulated glucose uptake were comparable for B cells of each genotype (Fig. 2D) . IL-7 stimulates increased glycolysis in and survival of T cells by pathways mediated in part by Stat5 (7) . The cytokine BAFF promotes mature B-cell glycolysis and survival (25) . However, neither PARP14 nor Stat6 influenced the effects of IL-7 or BAFF on B cells (Fig. 2E and Fig. S3 ). The dramatic IL-4 effect on gluose uptake likely reflects both the increased conversion of hexose through glycolytic demand and IL-4-induced induced increases in surface expression of transporters such as GLUT-1 that are PARP14-dependent (Fig. S4A) . We infer that there are specific physiological roles for IL-4, Stat6, and PARP14 in metabolic regulation and survival distinct from the BAFF and IL-7-Stat5 pathways.
To test whether the defect of PARP14-null B cells in IL-4-induced glycolysis is intrinsic to hematopoietic cells, we performed bone marrow reconstitutions. PARP14 is too large for efficient retrovirion generation, but the middle (three tandem "macrodomains") and C-terminal (catalytic ADP ribosyltransferase) portions (PARP14-MC) sufficed for its transcriptional function (13, 14) . Bone marrow cells lacking PARP14 were transduced with PARP14-MC cDNA or empty vector ("MiT"), and then used to reconstitute recipients (Fig. 3A) . Glycolysis and apoptosis were measured in B cells derived from transduced (Thy1.1
−/− marrow stem cells and compared with control samples. IL-4 did not increase glycolysis in B cells lacking PARP14 (MiT). In contrast, PARP14-MC-transduced B cells responded to IL-4 by enhanced glycolysis (Fig. 3B ) and the ability of IL-4 to rescue B cells from apoptosis (Fig. 3C) . We conclude that PARP14 plays a cell-intrinsic role in IL-4-regulated B-cell glycolysis and survival.
Essential Role for PARP14 in Mediating Mitochondrial Activity in B Cells. Mitochondrial stability and activity are crucial for cellular metabolism and apoptosis regulation after growth factor withdrawal. PARP14 mediates IL-4 induction of the prosurvival kinase Pim-1, which can impact energetics, and the mitochondrially associated Bcl-2-related protein Mcl-1 (15) . IL-4 enhanced mitochondrial respiration and membrane potential in WT B cells, but Parp14 −/− and Stat6 −/− B cells did not demonstrate this response (Fig. 4 A and B and Fig. S4B ). The glycolytic end product pyruvate can be metabolized to lactate or used by mitochondria after conversion to acetyl-CoA by pyruvate dehydrogenase (PDH). LPS stimulation increased lactate release by B cells but IL-4 did not, and lactate production by B cells of each genotype was comparable (Fig. 4C) . In contrast, IL-4 accelerated glucose oxidation (conversion of the 6-position carbon of glucose into CO 2 ) by a PARP14-and Stat6-dependent mechanism (Fig. 4D) . Consistent with this finding, PDH gene expression was lower in IL-4-stimulated lymphocytes lacking PARP14, and IL-4 increased expression of the citrate synthase gene in WT but not deficient B cells (Fig. 4E , Table S1 , and Fig.  S4D ). This effect on two key steps leading into the Krebs cycle appeared not to be a global defect of mitochondrial biogenesis or energy generation: Genes such as Sdha were unaffected, and fatty acid oxidation in the B cells was neither stimulated by IL-4 nor dependent on PARP14 (Fig. 4E and Fig. S4 C and E) . Thus, metabolism in B cells is coordinated after IL-4 stimulation so that a PARP14-dependent increase of glucose flux into pyruvate is used at least in part by greater mitochondrial respiration, with lactate production remaining constant. IL-4 enlarges resting B cells (24) , so we tested its effect on biosynthesis that would increase ATP consumption. IL-4 increased protein synthesis in B cells within 3 h, whereas treatment with the protein synthesis inhibitor anisomycin blocked this effect (Fig. 5A) . AMPK senses cellular energy status and signals increased glucose uptake, glycolysis, and mitochondrial activity (18). AMPK inhibitors (compound C or araA) reduced rates of protein synthesis in IL-4-treated cells to below those of unstimulated controls (Fig. 5A ). AMPK inhibition either with compound C or a well-established dominant-negative mutant decreased glycolysis rates of IL-4-stimulated B cells to control levels and reduced IL-4 protection from apoptosis ( Fig. 5 B-E) . Thus, IL-4-induced B-cell survival required adequate AMPK activity and an ability to increase glycolytic metabolism.
To explore the relationship among IL-4, glycolysis, and AMPK, and to validate the effects of pharmacological agents used to probe the relationships between metabolism and antiapoptotic signaling by IL-4, we analyzed phosphorylation of AMPK and its substrate ACC. These analyses revealed that IL-4 induced p-AMPK(T172) but not p-ACC(S79), and activation of the pathway was effectively blocked by compound C (Fig. 5F ). In contrast, inhibition of AMPK did not affect IL-4-induced p-Akt or p-Stat6 ( Fig. S5 B and C). We further explored the relationship of PARP14 and the metabolic response to survival signaling by using the AMPK activator metformin (18) to test its impact on the defects observed in PARP14-deficient B cells. In the presence of IL-4, metformin reverted the glycolytic, mitochondrial, and survival defects of Parp14-and Stat6-null B cells ( 
Absence of PARP14 Protects Against Myc-Induced Developmental
Block and Lymphoma. PARP14 is a member of the BAL family of macrodomain proteins implicated in the clinical aggressiveness of human B-cell lymphomas (17) . Moreover, the capacity to reprogram metabolism may be central to oncogenesis, and suppression of apoptosis accelerates B-lymphoid malignancy (8, 9, 26) . When we tested whether the absence of PARP14 from B cells influenced the prognosis for cancer-prone Eμ-myc transgenic mice (27) , the absence of PARP14 delayed lymphomagenesis (Fig. 6A ). Strikingly, PARP14 was required for the dramatic Myc-induced decrease in mature-phenotype B cells in premalignant marrow and deficit of follicular B cells in spleen ( Fig. 6B and Table 1 ), although Myc in the absence of PARP14 induced pre-B lymphomas similar to the main phenotype of Eμ-myc tumors (Fig. S6 ). Myc expression in this system forces increased cell size on B-lineage cells (27, 28) , but the absence of PARP14 from the B220 + population countered this in each subset ( Fig. 6C and Table S2 ). These effects were associated with decreased glycolysis in freshly isolated Parp14 −/− B cells compared with controls and a quantitatively similar blunting of the glycolytic response to Eμ-myc in premalignant B-lineage cells lacking PARP14 compared with Eμ-myc controls (Fig. 6D) . We further observed that survival signaling in Parp14 −/− B220 + Myctransgenic cells was impaired compared with Eμ-myc controls (Fig. 6E ), whereas the in vivo BrdU-labeling indices of Eμ-myc-transgenic B-lineage cells were unaffected by the lack of PARP14 (Fig. S7 ). These analyses of the premalignant bone marrow and spleen further highlight a striking mitigation of the impact of sustained Myc expression when PARP14 is absent. We conclude that expression of this B aggressive lymphoma family macro-PARP is vital for oncogenic and developmental effects of Myc as well as normal metabolic regulation of B cells.
Discussion
A fundamental insight from this study pertains to the biological functions of ADP ribosyltransferases, in particular those recently identified as intracellular monotransferases (29) . ADP ribosylation by endogenous activities of mammalian cells was first identified with PARP1, but 17-18 mammalian genes encode a module similar to the catalytic domain of PARP1 (30, 31) . Unlike PARP1, PARP14 appears to catalyze mono-and not poly-ADP ribosylation (29) . Furthermore, PARP14 is one of three members of the BAL family of PARPs containing macrodomains ("macro-PARPs") that bind (poly-)ADP ribose (32, 33 ). PARP1's roles in DNA repair, chromatin, and inflammation have been identified (30, 31) , but the physiological functions of monotransferase or macro-PARP family members are not known.
Increased macro-PARP gene expression is associated with worse clinical outcomes of DLBCL (17) , but there has been no direct evidence of an impact of these proteins on B-cell malignancy or of contributory mechanisms that could account for such a role. Our data indicate that PARP14 contributes to Mycinduced lymphoma pathobiology and provide evidence that PARP14 impacts two processes pertinent to B-lymphoid oncogenesis. First, PARP14 is vital for a coordinated metabolic effect whereby glycolysis and aspects of mitochondrial function are increased in a manner vital for IL-4-induced survival signaling of normal and premalignant Eμ-myc-expressing B-lineage cells. This role of PARP14 intersects with AMPK such that this central regulator of glycolysis coordinately restored glycolytic fitness and survival signaling when combined with IL-4. Second, this macro-PARP is vital for the impairment of developmental progression imposed by dysregulated c-Myc in the premalignant phase (27) , so that the pool of target cells (pro-, pre-, and overall numbers of B lineage-committed cells) is expanded by Eμ-myc far less if PARP14 is absent. This effect, along with the lack of impact on IL-7-treated B cells, distinguishes PARP14 facilitation of Eμ-myc perturbations of B-lymphoid physiology from recent findings on an IL-7 receptor-Stat5 pathway important for c-Myc-driven lymphomagenesis (10, 34) .
Reorganization of metabolism and a substantial increase in demands on the glycolytic pathway are features common among cancer cells, but the underlying molecular mechanisms effecting these changes are not clear. We found substantially increased glycolysis in premalignant B lineage-committed Eμ-myc bone marrow cells, consistent with the increased size of these cells and analyses of cell lines showing that c-Myc directly binds regulatory elements in the chromatin of genes encoding glycolytic enzymes to increase their expression (35) . Of note, we found that PARP14 is crucial for Eμ-myc cells fully to increase their glycolysis and size. Thus, the proliferative drive and faster protein synthesis forced by sustained c-Myc overexpression (27, 28) must contend with a restriction on the rate of glycolysis when PARP14 is absent. Rapid engulfment of apoptotic cells in vivo precludes accurately measuring rates of apoptosis in situ. However, BrdU incorporation into all B220 + subsets in vivo was similar in Parp14 +/+ and Parp14 −/− Eμ-myc mice, and the ex vivo data collectively indicate that PARP14 is vital for sustaining normal glycolytic rates in vivo and mitigates the apoptotic stress of Myc. Perturbations that decrease apoptotic susceptibility commonly potentiate Myc-induced lymphomagenesis (26, 36) . This suggests that the role of PARP14 in mediating regulation of B-cell metabolism and thereby enhancing survival is a significant component of its impact on oncogenesis.
The work also provides evidence of an interaction between AMPK activity and the prosurvival role of PARP14. The findings are intriguing in light of conflicting evidence from prior explorations of the relationship between AMPK and cell survival, and evidence of a metformin effect on cancer in patients with diabetes (37), discussed further in SI Discussion. AMPK mediates a prosurvival signal initiated by adiponectin treatment of cardiomyocytes after ischemia and reperfusion and is similarly protective against neuronal apoptosis (38, 39) . Conversely, sustained AMPK activation by high concentrations of an AMP analog caused apoptosis of normal and cancerous B cells and can similarly impact other cell types (40, 41) . These opposite outcomes were due either to cell type-specific differences or the degree of AMPK activation, its duration, and cross-talk in which AMPK inhibits signaling via mTOR or exercises ACC-independent functions (42) . In contrast to AMPK activation by stresses such as glucose deprivation, IL-4 stimulates mTOR (12) . Of note, in the absence of IL-4, constitutively increased AMPK neither improved survival signaling nor raised rates of glycolysis to the level of IL-4-stimulated cells. Although the main role of AMPK may be to promote metabolic fitness on a pathway parallel to the IL-4-PARP14 mechanism, such findings indicate that coordination of at least two distinct mechanisms downstream from the IL-4 receptor is crucial. Akt activation by IL-4 was unaffected by the absence of PARP14, and this kinase can regulate survival by a mechanism that involves enhancement of glycolysis in coordination with mitochondrial stabilization (1, 22) . Thus, although further study will be required to establish the nature of the PARP14-independent component(s), a contribution of Akt that cannot be replaced by AMPK is a straightforward model based on the data.
Finally, this work reveals that the capacity of Myc to impede B-cell maturation is strikingly dependent on PARP14. A block to B-lineage maturation in the bone marrow of Eμ-myc-transgenic mice has long been known (27) , but the basis for this effect is not understood and conditional loss of myc also led to a deficit of mature B cells (43) . Sustained c-Myc drives increased cell size along with persistent cell cycling and the attendant demand for increased energy production; the absence of PARP14 abrogated this increased size of B lineage-committed Eμ-myc cells. Developmental progression may require being able to exit the cell cycle (44), so it is tempting to speculate that the limitation in glycolysis prevented constant cycling, thereby allowing pre-B cells to mature. In addition, it is intriguing that bone marrow pre-B cells appeared more resistant to inhibition of glycolysis than their more mature IgM + progeny (45) . In any case, the emergence of lymphoma is thought to be due in part to the accumulation of an expanded pre-B population in Eμ-myc mice (27, 28) . Thus, the combined changes may account for the contribution of this BAL-family ADP ribosyltransferase to Mycinduced lymphomagenesis.
Materials and Methods
Mice and Bone Marrow Reconstitutions. B6, B6.Eμ-myc, B6.PL-Thy1a mice (The Jackson Laboratory), Parp14 −/− mice (15), backcrossed to C57BL/6 (B6; Thy1b) for 12 generations, and B6/129-intercrossed Stat6 −/− mice were housed in ventilated microisolators under specified pathogen-free conditions. Bone marrow cells were harvested after induction of donors with 5-fluorouracil, transduced with MiT vector or MiT-PARP14(MC) as described (13) , and transferred into irradiated recipients (46) . After 6 wk, B cells were isolated using magnetic beads, divided, cultured overnight ±IL-4, and assayed for apoptosis and glycolysis (modified by using 0. 3 H]deoxyglucose after depleting intracellular glucose stores (details in SI Materials and Methods). As detailed in SI Materials and Methods, purified B cells recounted after culture were assayed by measuring rates of mitochondrial oxidation of fluorescent compounds or determination of 14 CO 2 generation from [6-14 C]glucose. Lactate levels in the medium afterward were determined using a commercial kit.
ACKNOWLEDGMENTS.
We are indebted to D. Carling (AMPK mutant cDNAs) and N. Taylor and M. Sitbon (H2 RBD -EGFP protein preparations) for generous gifts of reagents. This work was initiated with support from Cancer Center Support Grant CA68485 and National Institutes of Health (NIH) Grants AI068149 (to M.B.), GM071735, and cores supported by DK020593, followed by Institutional Bridge funding from Vanderbilt University.
Supporting Information
Cho et al. 10 .1073/pnas.1017082108
SI Discussion
As noted in the main-text Discussion, there are epidemiological studies exploring the relationship between metformin and a variety of cancers, and metformin-treated patients appear to have decreases in some types of cancer (1, 2) . However, metformin is administered to patients to treat type II diabetes, commonly in association with obesity. Accordingly, the biological effects and epidemiological findings reflect a complex interplay among numerous variables-some of which are cancer cell-intrinsic but many of them extrinsic to the tumor cells. For instance, obesity and type II diabetes are now appreciated as commonly involving inflammation that is exacerbated or reinforced by the results of insulin resistance (3) (4) (5) . Inflammation in turn is understood to influence the emergence of cancers via the tumor microenvironment (6) . Moreover, the concentrations of blood sugar, other metabolic substrates (e.g., fatty acids), and hormones and cytokines such as IGF1 all impact both the nascent tumor cell and the host. All of these factors are affected by treatment with hypoglycemic agents such as metformin. Accordingly, although it has been reported that treatment of diabetics with metformin decreases their relative risk for some types of cancer (with little or no information about lymphomas) (1, 2), these studies cannot sort out the complex interplay among these multiple variables and, in particular, what are tumor cell-intrinsic effects.
Survival, proliferation, and developmental regulation can affect the emergence and progression of B lymphoma and other cancers. Our experiments showed that for the B lymphocyte, PARP14 promotes metabolic fitness and a higher probability of survival and that metformin can normalize these parameters for PARP14-deficient B-lineage cells. A reasonable and exciting inference supported but not proven by these findings is that they may highlight a dualistic impact of metabolism or metformin (or AMPK activation) as a feature of the findings about cancer. The enhanced metabolic fitness might, at the tumor cell-autonomous level, increase cancer fitness while decreasing risks in the setting of the organism as a whole. Such "Jekyll and Hyde" behavior is now appreciated for TGF-β, for instance (7) . Consistent with these points, evidence from metformin chemoprevention studies in a lung cancer model suggests that in this experimental setting, a protective influence of metformin is due not to its effects on the tumor cells themselves but rather to metformin's impact on the liver, that is, decreased production of circulating proteins such as IGF1 that enhance the cancer (1). This experimental evidence supports the important conceptual point that metformin systemically might attenuate cancers by indirect mechanisms, even though in the evolving cancer cell it might promote metabolic fitness.
SI Materials and Methods
Mice. Mice were housed in the Vanderbilt University mouse facility under Institutional Animal Care and Use Committee guidelines and used following approved protocols. With the exception of tumor incidence analyses, mice were used at 5-10 wk of age. For monitoring and scoring lymphoma incidence, Eμ-myc mice were maintained until scored as positive when compromised by disease with palpable tumor or clearly suffering or moribund, according to guidelines of the Institutional Animal Care and Use Committee and veterinary staff. IL-6, IL-3, and murine stem cell factor (SCF) were from Peprotech; and F(ab9) 2 of goat anti-mouse IgM was from Jackson ImmunoResearch Laboratories. GFP-Glut-1 ligand (H2 RBD -EGFP) fusion protein (8, 9 ) was a generous gift of N. Taylor and M. Sitbon (Universite de Montpellier, Montpellier, France). Mouse primary lymphocytes were cultured as described (10) . Depletion of Thy1 + cells from the splenocyte pool was performed using biotin-anti-Thyl.2 and streptavidin magnetic beads (BD IMag; BD Biosciences).
Bone Marrow Reconstitutions. Bone marrow cells from femurs and tibiae of 8-to 10-wk-old mice were harvested and transduced after induction of donors with 5-fluorouracil (11) . Transductions were performed using supernatants from ΦNX packaging cells 2 d after transfection with MiT vector or MiT-PARP14(MC) as described (10) . After expansion in Dulbecco's MEM supplemented with 15% FBS, 10 ng/mL IL-6, 6 ng/mL IL-3, and 100 ng/ mL SCF, transduced cells (2 × 10 6 per recipient) were injected i.v. into irradiated (8 Gy in two divided doses) WT mice (8-wkold). In parallel, controls (B6.PL-Thyla) received nontransduced marrow from WT and Parp14 −I− mice. After 6 wk, Thy1.1 + (transduced) and Thy1.1 − B cells were isolated from the spleens of recipient mice using negative selection with anti-CD3ε magnetic beads followed by enrichment with biotinylated anti-Thyl.l for positive and negative selection. The enriched cell populations were then divided, cultured overnight ±IL-4, and assayed for apoptosis and glycolysis (modified by using 0.3 × 10 cells per sample for the triplicates).
Flow Cytometry and Apoptosis Assays. Antibodies were from BD Biosciences unless otherwise indicated. Cells were analyzed using flow cytometry with a FACSCalibur (BD Biosciences) and FlowJo software (TreeStar) as described. TUNEL assays were performed as described (12) , using cells cultured (20 h) with or without IL-4 (5 ng/mL). Protection against apoptosis provided by IL-4 was quantitated using the formula ["% decrease in death" = (% TUNEL . Surface levels of Glut-1 were measured using a translational fusion with GFP with a Glut-1 ligand (H2 RBD -EGFP) (8, 9) . Cultured splenocytes were incubated with H2 RBD -EGFP at 37°C for 30 min, surface-stained for B220, and analyzed by flow cytometry.
Measurements of RNA and Protein Levels. Proteins in whole-cell extracts were separated by SDS/PAGE, transferred onto nylon membranes (Millipore), and then incubated with rabbit antibodies against phospho (p)-Akt (S473), p-Akt (T308), p-FOXOl/ 3a, p-GSK3p, Akt (Cell Signaling Technologies), and goat antiactin (Santa Cruz Biotechnology) Abs followed by the appropriate fluorophore-conjugated, species-specific secondary anti-Ig antibodies (Rockland Immunochemicals and LI-COR). Bands were visualized and quantitated as described (12) . RNA was isolated using TRIzol reagent (Invitrogen). After cDNA synthesis by reverse transcription, expression of metabolic genes was analyzed by quantitative real-time RT-PCR run in triplicate using SYBR Green (Applied Biosystems) and compared with levels of 36B4 as a control and the primer pairs detailed in Table  S1 . Data are presented as values normalized to WT control and averaged over three independent experiments.
Glucose Uptake and Glycolysis Assays. B cells (10 6 
